Collectively, our data indicate that GA appears to affect the interdependent activation of CD4+ T cells and glia, and that the regulatory effects of GA on the activity of STAT1 and −3 and the production of IL-2 may be an important molecular mechanism underlying the therapeutic action of GA on MS. The gene discussed is CD4; the disease is myeloid sarcoma.